Cart
sales@molnova.com
AGN-201904
CAS No. 651729-53-2
AGN-201904( —— )
Catalog No. M33962 CAS No. 651729-53-2
AGN-201904 is an omeprazole prodrug and proton pump inhibitor, which may delay aging and be used for the prevention and treatment of peptic ulcers.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 445 | Get Quote |
|
| 5MG | 686 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1398 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAGN-201904
-
NoteResearch use only, not for human use.
-
Brief DescriptionAGN-201904 is an omeprazole prodrug and proton pump inhibitor, which may delay aging and be used for the prevention and treatment of peptic ulcers.
-
DescriptionAGN-201904 is an omeprazole prodrug and proton pump inhibitor, which may delay aging and be used for the prevention and treatment of peptic ulcers.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetATPase
-
RecptorATPase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number651729-53-2
-
Formula Weight559.61
-
Molecular FormulaC25H25N3O8S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(O)COC1=CC=C(C=C1)S(=O)(=O)N2C(=NC=3C=C(OC)C=CC32)S(=O)CC4=NC=C(C(OC)=C4C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Oligomycin A
Oligomycin A, created by Streptomyces, acts as a mitochondrial F0F1-ATPase inhibitor, with a Ki of 1 μM.
-
3′,4′,7-Trihydroxyfl...
7,3',4'-Trihydroxyflavone inhibits osteoclastogenesis via the nuclear factor of activated T cells c1. 7,3',4'-Trihydroxyflavone can markedly inhibit the receptor activator of nuclear factor kappa B ligand-induced osteoclastic differentiation from mouse bone marrow-derived macrophages (BMMs).
-
Deslanoside
Deslanoside is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms. Deslanoside inhibits the Na-K-ATPase membrane pump resulting in an increase in intracellular sodium and calcium concentrations.
